InsidersTradesSigma
Follow the Coherus Oncology, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). The latest transaction was filed on 9 June 2026 (Attribution). Among the most active insiders: Newton Charles W.. Every trade is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
7 of 7 declarations
Coherus Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of biosimilar therapies for cancer treatment. It is listed on NASDAQ under the ticker CHRS.